Estradiol cypionate

Category:Intermediates
Product Name:Estradiol cypionate
CAS No.:313-06-4
Standard:In-house Standards
Price(USD):Interview
Company:Hanways Chempharm Co.,Limited

Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Wuhan

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Product name

    Estradiol Cypionate

    Synonyms

    Estradiol 17-Cypionate; estradiol 17-beta-cipionate; estradiol 17-beta-(3-cyclopentylpropionate); Oestradiol Cypionate; Estradiol Cypionate; 3-hydroxyestra-1,3,5(10)-trien-17-yl 3-cyclopentylpropanoate; (17beta)-3-hydroxyestra-1,3,5(10)-trien-17-yl 3-cyclopentylpropanoate; (8xi,9xi,14xi,17beta)-3-hydroxyestra-1,3,5(10)-trien-17-yl 3-cyclopentylpropanoate; Depofemin

    MOQ

    25KG

    CAS No.

    313-06-4

    Appearance

      An almost white powder

    Molecular Formula

    C26H36O3

    Molecular Weight

    396.5622

    Assay

    99%

    Application

    Pharma grade or research purpose

    Packing

    As per your request

    Storage

    Preserve in tight, light-resistant containers in a cool place

    Remarks

    NA

    Custom synthesis

    Available

    Supply Ability

    10000kg/month

     

    Medical use

     

    The medical uses of estradiol cypionate are the same as those of estradiol and other estrogens. Examples of indications for the drug include hormone therapy and hormonal contraception. In regard to the latter, estradiol cypionate has been used in combination with medroxyprogesterone acetate as a combined injectable contraceptive. Along with estradiol valerate, estradiol undecylate, and estradiol benzoate, estradiol cypionate is used as a form of high-dose estrogen therapy in feminizing hormone therapy for transgender women.

     

    Estradiol cypionate is usually used at a dosage of 1 to 5 mg by intramuscular injection every 3 to 4 weeks in the treatment of menopausal symptoms such as hot flashes and vaginal atrophy, at a dosage of 1.5 to 2 mg by intramuscular injection once a month in the treatment of female hypoestrogenism due to hypogonadism, and at a dosage of 2 to 10 mg by intramuscular injection once every 1 or 2 weeks for hormone therapy in transgender women.

Send your message to this supplier
  • From:
  • To:
    Hanways Chempharm Co.,Limited
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service